[go: up one dir, main page]

CA3058395C - Compositions et methodes de traitement des synucleinopathies - Google Patents

Compositions et methodes de traitement des synucleinopathies

Info

Publication number
CA3058395C
CA3058395C CA3058395A CA3058395A CA3058395C CA 3058395 C CA3058395 C CA 3058395C CA 3058395 A CA3058395 A CA 3058395A CA 3058395 A CA3058395 A CA 3058395A CA 3058395 C CA3058395 C CA 3058395C
Authority
CA
Canada
Prior art keywords
propylamino
tetrahydro
benzothiazole
amine
pramipexole
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3058395A
Other languages
English (en)
Other versions
CA3058395A1 (fr
Inventor
Thomas N. Chase
Kathleen E. Clarence-Smith
Original Assignee
Chase Therapeutics Corp
Alto Neuroscience Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chase Therapeutics Corp, Alto Neuroscience Inc filed Critical Chase Therapeutics Corp
Priority claimed from PCT/US2018/024344 external-priority patent/WO2018183192A1/fr
Publication of CA3058395A1 publication Critical patent/CA3058395A1/fr
Application granted granted Critical
Publication of CA3058395C publication Critical patent/CA3058395C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Abstract

La présente invention concerne l'utilisation d'un antagoniste de 5HT3, en combinaison avec une 6-propylamino-4,5,6,7-tétrahydro-1,3-benzothiazole-2-amine, pour réduire les effets secondaires et pour faciliter le traitement neuroprotecteur d'un patient souffrant d'un trouble synucléinopathique pour permettre une dose quotidienne de 6-propylamino-4,5,6,7-tétrahydro-1,3-benzothiazole-2-amine thérapeutiquement efficace sans effets secondaires limitant la dose provoqués par le pramipexole lorsqu'ils sont administrés seuls.
CA3058395A 2017-03-27 2018-03-26 Compositions et methodes de traitement des synucleinopathies Active CA3058395C (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762477187P 2017-03-27 2017-03-27
US62/477,187 2017-03-27
US201762528228P 2017-07-03 2017-07-03
US62/528,228 2017-07-03
PCT/US2018/024344 WO2018183192A1 (fr) 2017-03-27 2018-03-26 Compositions et méthodes de traitement des synucléinopathies

Publications (2)

Publication Number Publication Date
CA3058395A1 CA3058395A1 (fr) 2018-10-04
CA3058395C true CA3058395C (fr) 2025-09-23

Family

ID=

Similar Documents

Publication Publication Date Title
US11547700B2 (en) Compositions and methods for treating synucleinopathies
US20210338652A1 (en) Composition and use for the treatment of parkinson's disease and related disorders
EP3609495B1 (fr) Association comprenant un antagoniste de nk1 et méthode de traitement de synucléinopathies
CA3058395C (fr) Compositions et methodes de traitement des synucleinopathies